DDInter624 DDInter448
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is regulated by {v} (Gene) SIK2
SIK2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) downregulates {v} (Gene) DSTYK
DSTYK {u} (Gene) is bound by {v} (Compound) Crizotinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Crizotinib (Compound)
Efavirenz (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is regulated by SIK2 (Gene) and SIK2 (Gene) is bound by Crizotinib (Compound)
Efavirenz (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Efavirenz (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Efavirenz (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) downregulates DSTYK (Gene) and DSTYK (Gene) is bound by Crizotinib (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Crizotinib (Compound)